Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XBD173 in Pulmonary Arterial Hypertension (PAH)
NCT07697183Phase 1Enrolling by invitation
- Sponsor
- Imperial College London
- Start
- May 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emapunil in pulmonary arterial hypertension (PAH), sponsored by Imperial College London. Primary endpoint: Changes in endothelial cell dysfunction associated with changes in total pulmonary resistance at 6 weeks. Started May 2026; status: enrolling by invitation.
02
Drugs
emapunil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07697183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697183.